THERAPY

News in brief ...

• Interindividual differences or changes in protein binding of cladribine are unlikely to influence its pharmacological effects in patients with leukaemia. So say Swedish researchers, who determined the degree of binding of cladribine to plasma proteins in healthy volunteers, and in patients with haematological malignancies. Whether cladribine affects the degree of binding of concomitantly administered drugs remains to be determined, comment these researchers. AlbcnIOnl F. et aI Protem bindmg of 2-chloro 2' ·dcoxyadenosme (c1adribme) m healthy subjects and m paucms wlth leukaemia European Journal ofClimcal

Pharmacology 46: 563·564. ~o. 6. 1994 .,,""

0156·270319410957·000191$01.00° Adi. International Limited 1994. All rights resarvecl

19

INPHARMAa 1 Oct 1994